The BioCentury Show:
Scaling Singapore Biotech
Speaking on The BioCentury Show, CEO Khoo Shih discussed ClavystBio’s global strategy for capitalizing on the ascendant energy and attention being devoted to Singapore biotech.
Posted on 16 Feb 2024
Fostering Venture Creation
Drug discovery and development are long term endeavors that require partnership and commitment across the ecosystem. 65LAB partners Thomas Hanke (Evotec), Christina Isacson (Lightstone Ventures), and Koh Shuwen (NUS) discuss what it takes to foster venture creation and build global biotech companies.
65LAB is a unique company creation vehicle established by ClavystBio, Evotec, Leaps by Bayer, Lightstone Ventures, Polaris Partners, and the Polaris Innovation Fund to leverage breakthrough science from A*STAR, DUKE-NUS and NUS for human health impact.
Posted on 27 Nov 2023
The Growing Pains of Getting a Product Into Clinic
Posted on 11 Sep 2023
Building a Biotech Company Across Two Continents
Posted on 10 Jan 2023
The Chemistry of Academia and Industry
Posted on 01 Dec 2022